Abstract C39: Phase I clinical trial of CX‐4945: A first‐in‐class orally administered small molecule inhibitor of protein kinase CK2

Author(s):  
Robert F. Marschke ◽  
Eleni Andreopoulou ◽  
Daniel D. Von Hoff ◽  
John K.C. Lim ◽  
Claire S. Padgett ◽  
...  
2013 ◽  
Author(s):  
Amol Padgaonkar ◽  
Olga Rechkoblit ◽  
Stephen Cosenza ◽  
Venkat R. Pallela ◽  
Venkata Subbaiah DRC ◽  
...  

2010 ◽  
Vol 9 (5) ◽  
pp. 1136-1146 ◽  
Author(s):  
Kuzhuvelil B. Harikumar ◽  
Ajaikumar B. Kunnumakkara ◽  
Nobuo Ochi ◽  
Zhimin Tong ◽  
Amit Deorukhkar ◽  
...  

2015 ◽  
Vol 35 (6) ◽  
Author(s):  
Lijs Beke ◽  
Cenk Kig ◽  
Joannes T. M. Linders ◽  
Shannah Boens ◽  
An Boeckx ◽  
...  

Protein kinase MELK has oncogenic properties and is highly overexpressed in some tumors. In the present study, we show that a novel MELK inhibitor causes both the inhibition and degradation of MELK, culminating in replication stress and a senescence phenotype.


Sign in / Sign up

Export Citation Format

Share Document